**NeueHealth Reports Solid Q2 2024 Financial Results**

**NeueHealth Reports Solid Q2 2024 Financial Results** NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE) has reported its financial results for the second quarter ending June 30, 2024. ### Key Financial Metrics | Metric | Q2 2024 | Consensus Estimates | Difference with Estimates | |---------------------------|------------------|---------------------|---------------------------| | Total Revenue | $252.48M | $252.48M | In line | | Earnings Per Share (EPS) | -$3.26 | -$3.26 | In line | NeueHealth has performed in line with market expectations this quarter, posting a total revenue of $252.48 million and an EPS of -$3.26, consistent with Wall Street consensus estimates. The company did not provide comparative figures for Q1 2024 or Q2 2023. ### Segment Revenue Performance | Segment | Q2 2024 Revenue | Previous Guidance | Difference | |------------------|------------------|-------------------|------------| | NeueCare | N/A | $320M | N/A | | NeueSolutions | N/A | $640M | N/A | While NeueHealth has not broken down the Q2 2024 revenue by segments, the company reiterated its guidance for the full year, with NeueCare expected to generate around $320 million and NeueSolutions $640 million. ### Financial Outlook - **Full Year 2024 Revenue Guidance:** $950 million - **Adjusted EBITDA:** Between $15 million and $25 million - **Adjusted Operating Cost Ratio:** Expected to be between 15%-16%, excluding corporate costs (19%-20% including corporate costs) ### Executive Comments Mike Mikan, President and CEO of NeueHealth, highlighted that the company has continued to build momentum in the second quarter by driving solid results across its segments, NeueCare and NeueSolutions. He stated, "We have built strong, ongoing relationships with consumers, providers, and payors across the healthcare industry." ### Dividends and Share Repurchase Programs There has been no announcement regarding any dividends or share repurchase programs in this earnings release. ### Forward Guidance NeueHealth expects to reach the high end of its guidance range for consumers served by the end of the year, reaffirming its Adjusted EBITDA guidance for the full year. ### Stock Price Movement Following the earnings release, NeueHealth's stock price saw a marginal decline of 0.28%. Overall, NeueHealth has shown a stable financial performance in Q2 2024, meeting consensus estimates and reinforcing positive outlooks for the remainder of the year.